Mid-term Business Plan 2027 Position we aspire to establish by 2033 This information is based on the "Mid-term Business Plan 2027" announced in April 2023. This information is based on the "Mid-term Business Plan 2027" announced in April 2023.
Introduction

We aim to establish ourselves as a Global Specialized Player by 2033.
With a focus on the Psychiatry & Neurology and Oncology as priority disease areas, Sumitomo Pharma Group (the “Group”) will contribute to the betterment of healthcare and fuller lives of people worldwide through diverse approaches, including pharmaceutical products, regenerative medicine/cell therapy, and non-pharmaceutical solutions. In other areas, too, the Group will leverage its assets to deliver value to patients. With this, the Group aims to establish itself as a Global Specialized Player (“GSP”) by 2033.
The basic strategy of the Mid-term Business Plan 2027 (FY2023-FY2027), which was formulated in April 2023, is to make a “qualitative transformation” of the business structure and business practices.
In the meantime, the Company will build a foothold for achieving renewed growth after the expiration of the exclusive marketing period for LATUDA® (atypical antipsychotic) in the U.S. and for establishing a position as a GSP.
Approach to 2033
Establish position as a Global Specialized Player (GSP)
We will establish a unique position globally by contributing to the betterment of healthcare and fuller lives of people worldwide through diverse approaches including pharmaceutical products, Regenerative Medicine/Cell Therapy, and non-pharmaceutical solutions, focusing on the Psychiatry & Neurology, and Oncology areas as our priority disease areas.
-
-
Small molecule
Molecular
design/synthesis
based on accumulated
experience/know-how -
Regenerative
medicine/cell therapyKnow-how acquired by
pioneering initiatives -
Non-pharmaceutical
(Frontier)To be developed
in the
mental
resilience area -
Other modalities
Pursuit of optimal
modalities
-
Psychiatry & Neurology Area
Diverse approaches to innovate the
conventional treatment system- Our core area
- Accumulated data, experience, and know-how
-
Oncology Area
Distinguished products to innovate
standard treatment- Carefully selected R&D pipeline
- Unique fundamentals for drug discovery
-
Other Areas
Deliver value to patients by
leveraging our assets- Women’s health issues, urological diseases, diabetes
- Rare diseases, infectious diseases
-